|
Prenosis will use its precision medicine platform to analyse biospecimens and data from BioAegis’ Phase II BTI-203 trial.
|
 |
|
Denosumab therapies are used to increase bone mass and treat osteoporosis, as well as address bone complications in cancer.
|
|
|
Lilly now has a lentiviral and LNP-based platform for in vivo delivery under its belt, which analyst Jack Cuthbertson says will give the company a broader chance for success.
|
|
|
The new site will focus on the use of AI models for purposes including the discovery and development of targeted medicines for patients with unmet medical needs.
|
|
|
Aicuris’ overall revenue is anticipated to reach $500m by 2030, not including AIC468.
|
|
